Oric Pharmaceuticals Inc (ORIC) is a Healthcare · Biotechnology company listed on NASDAQ. Price $12.72 (-1.24%), Market cap $0.84B, 52-week low–high $5.14 ~ $14.41.
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under
Financial statements, price targets, institutional (13F) holdings and related news for Oric Pharmaceuticals Inc are updated in real time on BlackAll Trade.
Oric Pharmaceuticals Inc trades at $12.72 (-1.24%). Real-time quotes and charts are available on BlackAll Trade.
Oric Pharmaceuticals Inc has a market cap of about $0.84B.
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its